Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 5/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27282016 | 1.00 | L3MBTL3 (0.42) | L3MBTL3HRH3DRD3DRD2CYP2D6 | |
| SCHEMBL27282631 | 1.00 | L3MBTL3 (0.42) | L3MBTL3HRH3DRD3DRD2CYP2D6 | |
| SCHEMBL30379435 | 0.89 | GNAI3 (0.41) | L3MBTL3DRD3DRD2DRD1DRD4 | |
| SCHEMBL9869321 | 0.89 | GNAI3 (0.41) | L3MBTL3DRD3DRD2DRD1DRD4 | |
| SCHEMBL13167818 | 0.88 | HRH3 (0.45) | HRH3DRD2 | |
| SCHEMBL6920677 | 0.87 | GNAO1 (0.47) | DRD3DRD2DRD1DRD4DRD5 | |
| SCHEMBL17351087 | 0.85 | GNAO1 (0.50) | DRD3DRD2DRD1DRD4DRD5 | |
| SCHEMBL24661958 | 0.83 | — | — | |
| SCHEMBL24662678 | 0.83 | — | — | |
| SCHEMBL9870758 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020156323-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-08-06 | — | — | WO | disclosed |
| US-20170166577-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE | 2017-06-15 | — | — | US | disclosed |
| WO-2015050472-A1 | FUSED INDOLE COMPOUNDS AND METHODS OF USING SAME | OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOST'YU "PANACELA LABS" (RU) | 2015-04-09 | — | — | WO | disclosed |
| US-5063228-A | 4-(substitutedaminoethyl)-3,4-dihydro-2-alkylpyrimido[1,6-a]benzimidazol-1(2H)-ones as antiarrhythmic agents | A. H. ROBBINS COMPANY, INCORPORATED (US) | 1991-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166577-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | APLNR, AP1G1, APMAP | L3MBTL3 3164/4885HRH3 1113/4885DRD3 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.